Citations

Showing 10 of 108094 citations.

Heparin-Induced Thrombocytopenia in COVID-19
Shah, Surbhi , Habib, Alma

Mayo Clinic

The Hematologist | June 23, 2022 | Volume: 19 | Issue: 4 | Pages: No page available

10.1182/hem.v19.4.202248 Get It

Putting the Novel Back in Oral Anticoagulants: Phase II Results of the Factor XIa Inhibitor Asundexian
Houghton, Damon E.

Mayo Clinic

The Hematologist | June 23, 2022 | Volume: 19 | Issue: 4 | Pages: No page available

10.1182/hem.v19.4.202244 Get It

Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601
Tang, Ming , Schipper, Matthew J. , Sandler, Howard M. , Zumsteg, Zachary S. , Efstathiou, Jason A. , Shipley, William U. , Seiferheld, Wendy, Lukka, Himanshu, Bahary, Jean-Paul , Zietman, Anthony L., Pisansky, Thomas M. , Zeitzer, Kenneth L. , Hall, William A. , Dess, Robert T. , Lovett, R.D., Balogh, Alexander G., Feng, Felix Y. , Spratt, Daniel E. , Jackson, William C , Tang, Ming , Sandler, Howard M , Zumsteg, Zachary S , Efstathiou, Jason A , Zeitzer, Kenneth L , Hall, William A , Dess, Robert T , Feng, Felix Y , Spratt, Daniel E , Jackson, Will

Mayo Clinic

Journal of Clinical Oncology | June 23, 2022 | Volume: 40 | Issue: 27 | Pages: 3172-3179

10.1200/jco.21.02741 | PMID 35737923 Get It

PURPOSE Metastasis-free survival (MFS), but not event-free survival, is a validated surrogate end point for overall survival (OS) in men treated for localized prostate cancer. It remains unknown if this holds true in biochemically recurrent disease after radical prostatectomy. Leveraging NRG/RTOG 9601, we aimed to determine the performance of intermediate clinical end points (ICEs) as surrogate end points for OS in recurrent prostate cancer. MATERIALS AND METHODS NRG/RTOG 9601 randomly assigned 760 men with recurrence after prostatectomy to salvage radiation therapy with 2 years of placebo versus bicalutamide 150 mg daily. ICEs assessed were biochemical failure (BF) per NRG/RTOG 9601 (prostate-specific antigen nadir + 0.3-0.5 ng/mL or initiation of salvage hormone therapy; [BF1]) and NRG/RTOG 0534 (prostate-specific antigen nadir+2 ng/mL; [BF2]), distant metastasis (DM), and MFS (DM or death). Surrogacy was assessed by the Prentice criteria and a two-stage meta-analytic approach (condition one assessed at the patient level with Kendall's τ and condition two assessed by randomly dividing the entire trial cohort into 10 pseudo trial centers and calculating the average R2 between treatment hazard ratios for ICE and OS). RESULTS BF1, BF2, DM, and MFS satisfied the four Prentice criteria. However, with the two-condition meta-analytic approach, there was strong correlation between MFS and OS (τ = 0.86), moderate correlation between DM and OS (τ = 0.66), and weaker correlation between BF1 (τ = 0.25) or BF2 (τ = 0.40) and OS. Similarly, for condition two, the treatment effect of antiandrogen therapy on MFS and OS were correlated ( R2 = 0.67), but this was not true for BF1 ( R2 = 0.09), BF2 ( R2 = 0.12), or DM ( R2 = 0.18) and OS. CONCLUSION MFS is also a strong surrogate for OS in men receiving salvage radiation therapy for recurrence after prostatectomy. Caution should be used when inferring survival benefit from effects on BF in biochemically recurrent prostate cancer. Lack of comorbidity data did not allow us to assess whether BF in men with no/minimal comorbidity could serve as a surrogate for OS.
Impact of Surgical Rejuvenation on Visual Processing and Character Attribution of Periorbital Aging
Boonipat, Thanapoom , Lin, Jason , García–Gonzalo, Esperanza , Bite, Uldis, Stotland, Mitchell A. , Abu-Ghname, Amjed, Garcia-Gonzalo, Esperanza, Abu‐Ghname, Amjed

Mayo Clinic

Plastic & Reconstructive Surgery | June 23, 2022 | Volume: 150 | Issue: 3 | Pages: 539-548

10.1097/prs.0000000000009458 | PMID 35749255 Get It

Background: The perceptual response to aging changes in the periorbital region and the effects of surgical rejuvenation on that response have not been elucidated. The authors examined the reflexive visual response to periorbital aging before and after brow lift and upper blepharoplasty surgery and investigated how observers’ character attributions of the images were affected by the rejuvenative intervention. Methods: Preoperative and postoperative photographs were obtained of patients with brow ptosis and dermatochalasis who underwent brow lift and blepharoplasty. Forty observers examined each image while an infrared eye-tracking camera continuously recorded their eye movements. The observers rated the images with respect to character attributes (attractiveness, trustworthiness, sociability, healthiness, and capability) on a scale of one to seven. Results: Fourteen patients who underwent brow lift and blepharoplasty were identified and studied. The surgical intervention was found to increase observers’ attention to the eye and brow region, while decreasing relative attention to the forehead and lower eyelid areas; increase the two-dimensional surface area of the forehead and eye and brow zones in a manner directly associated with the measured changes in visual attention; and significantly increase the ratings for all five positively valanced character attributes compared with preoperative controls. Conclusions: The authors provide an important combination of explicit and implicit data illustrating how surgical rejuvenation unveils the periorbital region to the observer. This change in pattern of inspection was associated with an improvement in the perception of character.
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
Muchtar, Eli , Gertz, Morie A. , LaPlant, Betsy, Buadi, Francis K. , Leung, Nelson , O’Brien, Patrick, Bergsagel, P. Leif , Fonder, Amie , Hwa, Yi L. , Hobbs, Miriam, Helgeson, Dania K., Bradt, Erin E., Lacy, Martha Q. , Kapoor, Prashant , Siddiqui, Mustaqeem , Larsen, Jeremy T. , Warsame, Rahma , Hayman, Suzanne R. , Dingli, David , Kourelis, Taxiarchis , Kumar, Shaji , Bergsagel, P. Leif , Lacy, Martha Q , Siddiqui, Mustaqeem A , Warsame, Rahma , Kourelis, Taxiarchis , Dispenzieri, Angela , Kumar, Shaji K , Gertz, Morie A , Leung, Nelson , Muchtar, E , Buadi, Francis K , Dingli, David , Helgeson, Dania Kaehlyn, Gonsalves, Wilson I. , Go, Ronald S. , Dispenzieri, Angela , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | June 23, 2022 | Volume: 6 | Issue: 18 | Pages: 5429-5435

10.1182/bloodadvances.2022007781 | PMID 35737873 Get It

Abstract Bortezomib, a proteasome inhibitor (PI), has shown efficacy in the treatment of newly diagnosed and relapsed light chain (AL) amyloidosis, and is often used in combination with cyclophosphamide and dexamethasone. Ixazomib is the first oral PI to be approved in routine practice but has not yet been evaluated in the upfront treatment setting. Newly diagnosed AL amyloidosis patients with measurable disease and adequate organ function were enrolled. The primary objective was to determine the hematologic response rate of ixazomib in combination with cyclophosphamide and dexamethasone. Treatment was given for 12 cycles, followed by ixazomib maintenance until progression. Thirty-five patients were included; their median age was 67 years, and 69% were male. Major organ involvement included heart (66%) and kidneys (54%). A median of 4 induction cycles (range, 1-12) were administered. The overall hematologic response to induction was 63% and included complete response in 11.4% and very good partial response in 37.1% of patients. One patient was upstaged to complete response during maintenance. The most common reason for going off study was the institution of alternate therapy (61%). With a median follow-up of 29.7 months for the living patients, the 2-year progression-free survival and overall survival were 74% and 78%, respectively. The median time to alternate therapy was 7.5 months. Grade ≥3 hematologic and nonhematologic adverse events occurred in 23% and 49% of patients. Given ixazomib’s favorable toxicity profile, which is an important advantage for the typically frail AL population, further evaluation of ixazomib in other combinations in the upfront setting is warranted. This trial was registered at www.clinicaltrials.gov as #NCT01864018.
The AI Needed for Ethical Decision Making Does Not Exist
Barwise, Amelia , Barwise, Amelia K , Pickering, Brian

Mayo Clinic

The American Journal of Bioethics | June 23, 2022 | Volume: 22 | Issue: 7 | Pages: 46-49

10.1080/15265161.2022.2075052 | PMID 35737497 Get It

P1389: RUXOLITINIB DEMONSTRATES A GREATER CORTICOSTEROID-SPARING EFFECT THAN BEST AVAILABLE THERAPY IN PATIENTS WITH CORTICOSTEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-VS-HOST DISEASE
Zeiser, R., Hashmi, Sharukh, Sarkar, R. , Gowda, Maanasa, Gunes, S., Stefanelli, Tommaso , Lee, S. J., Teshima, T., Zeiser, R., Russo, Domenico , Ram, Ron , Chakraverty, Ronjon , Middeke, Jan Moritz , Giebel, Sebastian , Gunes, S., Locatelli, F.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1273-1274

10.1097/01.hs9.0000848416.66197.62 Get It

Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
Etra, Aaron , Gergoudis, Stephanie, Morales, George , Spyrou, Nikolaos , Shah, Jay , Kowalyk, Steven, Ayuk, Francis , Baez, Janna , Chanswangphuwana, Chantiya , Chen, Yi‐Bin , Choe, Hannah , DeFilipp, Zachariah , Gandhi, Isha , Holler, Ernst , Kapoor, Urvi , Kitko, Carrie L. , Lin, Jung-Yi, Pawarode, Attaphol , Rösler, Wolf, Schechter, Tal , Hyfte, Grace Van , Weber, Daniela , Wölfl, Matthias , Young, Rachel , Özbek, Umut , Ferrara, James L.M. , Hexner, Elizabeth , Lin, Jung-Yi , Merli, Pietro , Pulsipher, Michael A. , Qayed, Muna , Levine, John E , Spyrou, Nikolaos , Hexner, Elizabeth O. , Hogan, William J. , Kraus, Sabrina , Malki, Monzr M. Al , Reshef, Ran , Levine, John E.

Mayo Clinic

Blood Advances | June 23, 2022 | Volume: 6 | Issue: 12 | Pages: 3707-3715

10.1182/bloodadvances.2022007296 | PMID 35443021 Get It

Abstract We used a rigorous PRoBE (prospective-specimen collection, retrospective-blinded-evaluation) study design to compare the ability of biomarkers of systemic inflammation and biomarkers of gastrointestinal (GI) tissue damage to predict response to corticosteroid treatment, the incidence of clinically severe disease, 6-month nonrelapse mortality (NRM), and overall survival in patients with acute graft-versus-host disease (GVHD). We prospectively collected serum samples of newly diagnosed GVHD patients (n = 730) from 19 centers, divided them into training (n = 352) and validation (n = 378) cohorts, and measured TNFR1, TIM3, IL6, ST2, and REG3α via enzyme-linked immunosorbent assay. Performances of the 4 strongest algorithms from the training cohort (TNFR1 + TIM3, TNFR1 + ST2, TNFR1 + REG3α, and ST2 + REG3α) were evaluated in the validation cohort. The algorithm that included only biomarkers of systemic inflammation (TNFR1 + TIM3) had a significantly smaller area under the curve (AUC; 0.57) than the AUCs of algorithms that contained ≥1 GI damage biomarker (TNFR1 + ST2, 0.70; TNFR1 + REG3α, 0.73; ST2 + REG3α, 0.79; all P < .001). All 4 algorithms were able to predict short-term outcomes such as response to systemic corticosteroids and severe GVHD, but the inclusion of a GI damage biomarker was needed to predict long-term outcomes such as 6-month NRM and survival. The algorithm that included 2 GI damage biomarkers was the most accurate of the 4 algorithms for all endpoints.
P1323: PREDICTION OF NON-RELAPSE MORTALITY BY EASIX AND HCT-CI SCORES IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
Baranwal, A., Mangaonkar, Abhishek A. , Litzow, Mark R. , Patnaik, Mrinal M. , Shah, Meera , Hogan, William J. , Alkhateeb, Hassan B.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1208-1209

10.1097/01.hs9.0000848156.17726.a5 Get It

P1287: DISTINGUISHING BETWEEN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA USING THE LYMPH3CX GENE EXPRESSION PROFILING ASSAY
Robetorye, Ryan S. , Ramsower, Colleen , McKinney, C. L., Rimsza, Lisa M.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1172-1173

10.1097/01.hs9.0000848012.06176.ae Get It